[
1. Trapeznikov NN, Poddubnaya IV. Handbook of Oncology. Editor Academician of the Russian Academy of Medical Sciences. Moscow: Kappa; 1996.
]Search in Google Scholar
[
2. Sanchez-Vega F, Mina M, Armenia J, Chatila WK, Luna A, La KC, et al. Oncogenic signaling pathways in the cancer genome atlas. Cell. 2018;173(2):32137.e10. DOI: 10.1016/j.cell.2018.03.035.10.1016/j.cell.2018.03.035607035329625050
]Search in Google Scholar
[
3. Pollard T, Earnshaw W, Lippincott-Schwartz J, Johnson G. Cell biology. 3rd edition. Philadelphia, PA: Elsevier; 2017.
]Search in Google Scholar
[
4. Ezkurdia I, Juan D, Rodriguez J M, Frankish A, Diekhans M, Harrow J, et al. Multiple evidence strands suggest that there may be as few as 19,000 human protein-coding genes. Hum Mol Genet. 2014;23(22):5866-78. DOI: 10.1093/hmg/ddu309.10.1093/hmg/ddu309420476824939910
]Search in Google Scholar
[
5. Malarkey DE, Hoenerhoff M, Maronpot RR. Carcinogenesis: mechanisms and manifestations. In: Bolon B, Haschek W, Rousseaux C, Ochoa R, Wallig M. Haschek and Rousseaux’s handbook of toxicologic pathology. 3rd Edition. Academic Press; 2013, p.107-46.10.1016/B978-0-12-415759-0.00005-4
]Search in Google Scholar
[
6. Becnel LB, Ochsner SA, Darlington YF, McOwiti A, Kankanamge WH, Dehart M, et al. Discovering relationships between nuclear receptor signaling pathways, genes, and tissues in Transcriptomine. Sci Signal. 2017;10(476):eaah6275. DOI: 10.1126/scisignal.aah6275.10.1126/scisignal.aah627528442630
]Search in Google Scholar
[
7. Ochsner SA, Abraham D, Martin K, Ding W, McOwiti A, Kankanamge W, et al. The Signaling Pathways Project, an integrated ‘omics knowledgebase for mammalian cellular signaling pathways. Sci Data. 2019;6(1):252. DOI: 10.1038/s41597-019-0193-4.10.1038/s41597-019-0193-4682342831672983
]Search in Google Scholar
[
8. Pecorino L. Molecular biology of cancer: mechanisms, targets, and therapeutics. 3rd edition. Oxford University Press; 2012.
]Search in Google Scholar
[
9. Yoo M, Hatfield DL. The cancer stem cell theory: Is it correct? Mol Cells. 2008;26(5):514-6.
]Search in Google Scholar
[
10. Reinhardt HC, Yaffe MB. Kinases that control the cell cycle in response to DNA damage: Chk1, Chk2, and MK2. Curr Opin Cell Biol. 2009;21(2):245-55. DOI: 10.1016/j.ceb.2009.01.018.10.1016/j.ceb.2009.01.018269968719230643
]Search in Google Scholar
[
11. Nigg EA. Mitotic kinases as regulators of cell division and its checkpoints. Nat Rev Mol Cell Biol. 2001;2:21-32.10.1038/3504809611413462
]Search in Google Scholar
[
12. Lim S, Kaldis P. Cdks, cyclins and CKIs: roles beyond cell cycle regulation. Development. 2013;140(15):3079-93. DOI: 10.1242/dev.091744.10.1242/dev.09174423861057
]Search in Google Scholar
[
13. Gopinathan L, Ratnacaram CK, Kaldis P. Established and novel Cdk/cyclin complexes regulating the cell cycle and development. Results Probl Cell Differ. 2011;53:365-89. DOI: 10.1007/978-3-642-19065-0_16.10.1007/978-3-642-19065-0_1621630153
]Search in Google Scholar
[
14. Kato S, Schwaederle M, Daniels GA, Piccioni D, Kesari S, Bazhenova L, et al. Cyclin-dependent kinase pathway aberrations in diverse malignancies: clinical and molecular characteristics. Cell Cycle. 2015;14(8):1252-9. DOI: 10.1080/15384101.2015.1014149.10.1080/15384101.2015.1014149461486725695927
]Search in Google Scholar
[
15. Foster SS, De S, Johnson LK, Petrini JH, Stracker TH. Cell cycle- and DNA repair pathway-specific effects of apoptosis on tumor suppression. Proc Natl Acad Sci U S A. 2012;109(25):9953-8. DOI: 10.1073/pnas.1120476109.10.1073/pnas.1120476109
]Search in Google Scholar
[
16. Mazouzi A, Velimezi G, Loizou JI. DNA replication stress: causes, resolution and disease. Exp Cell Res. 2014;329(1):85-93. DOI: 10.1016/j.yexcr.2014.09.030.10.1016/j.yexcr.2014.09.030
]Search in Google Scholar
[
17. Visconti R, Della Monica R, Grieco D. Cell cycle checkpoint in cancer: a therapeutically targetable double-edged sword. J Exp Clin Cancer Res. 2016;35(1):153. DOI: 10.1186/s13046-016-0433-9.10.1186/s13046-016-0433-9
]Search in Google Scholar
[
18. Rubin SM. Deciphering the retinoblastoma protein phosphorylation code. Trends Biochem Sci. 2013;38(1):12-9. DOI: 10.1016/j.tibs.2012.10.007.10.1016/j.tibs.2012.10.007
]Search in Google Scholar
[
19. DeCaprio JA, Ludlow JW, Lynch D, Furukawa Y, Griffin J, Piwnica-Worms H, et al. The product of the retinoblastoma susceptibility gene has properties of a cell cycle regulatory element. Cell. 1989;58(6):1085-95. DOI: 10.1016/0092-8674(89)90507-2.10.1016/0092-8674(89)90507-2
]Search in Google Scholar
[
20. Pardal R, Molofsky AV, He S, Morrison SJ. Stem cell self-renewal and cancer cell proliferation are regulated by common networks that balance the activation of proto-oncogenes and tumor suppressors. Cold Spring Harb Symp Quant Biol. 2005;70:177-85. DOI: 10.1101/sqb.2005.70.057.10.1101/sqb.2005.70.05716869752
]Search in Google Scholar
[
21. Mesplede T, Gagnon D, Bergeron-Labrecque F, Azar I, Senechal H, Coutlee F, et al. p53 degradation activity, expression, and subcellular localization of E6 proteins from 29 human papillomavirus genotypes. J Virol. 2012;86(1):94-107. DOI: 10.1128/JVI.00751-11.10.1128/JVI.00751-11325587522013048
]Search in Google Scholar
[
22. El-Deiry WS. p21(WAF1) mediates cell-cycle inhibition, relevant to cancer suppression and therapy. Cancer Res. 2016;76(18):5189-91. DOI: 10.1158/0008-5472.CAN-16-2055.10.1158/0008-5472.CAN-16-2055502810827635040
]Search in Google Scholar
[
23. Otto T, Sicinski P. Cell cycle proteins as promising targets in cancer therapy. Nat Rev Cancer. 2017;17(2):93-115. DOI: 10.1038/nrc.2016.138.10.1038/nrc.2016.138534593328127048
]Search in Google Scholar
[
24. Manning G, Whyte DB, Martinez R, Hunter T, Sudarsanam S. The protein kinase complement of the human genome. Science. 2002;298(5600):191234. DOI: 10.1126/science.1075762.10.1126/science.107576212471243
]Search in Google Scholar
[
25. Wallace MD, Southard TL, Schimenti KJ, Schimenti JC. Role of DNA damage response pathways in preventing carcinogenesis caused by intrinsic replication stress. Oncogene. 2014;33(28):3688-95. DOI: 10.1038/onc.2013.339.10.1038/onc.2013.339393600423975433
]Search in Google Scholar
[
26. Polatova DS. 413P - The state of molecular biological markers in osteosarcoma. Ann Oncol. 2019;30(Suppl 9):ix138.10.1093/annonc/mdz433.010
]Search in Google Scholar
[
27. Malik-Rachline G, Hacohen-Lev-Ran A, Seger R. Nuclear ERK: Mechanism of translocation, substrates, and role in cancer. Int J Mol Sci. 2019;20(5):1194. DOI: 10.3390/ijms20051194.10.3390/ijms20051194642906030857244
]Search in Google Scholar
[
28. Grimaldi AM, Simeone E, Festino L, Vanella V, Strudel M, Ascierto PA. MEK Inhibitors in the treatment of metastatic melanoma and solid tumors. Am J Clin Dermatol. 2017;18(6):745-54. DOI: 10.1007/s40257-017-0292-y.10.1007/s40257-017-0292-y28537004
]Search in Google Scholar
[
29. Bustelo XR. RHO GTPases in cancer: known facts, open questions, and therapeutic challenges. Biochem Soc Trans. 2018;46(3):741-60. DOI: 10.1042/BST20170531.10.1042/BST2017053129871878
]Search in Google Scholar
[
30. Kidger AM, Sipthorp J, Cook SJ. ERK1/2 inhibitors: New weapons to inhibit the RAS-regulated RAF-MEK1/2-ERK1/2 pathway. Pharmacol Ther. 2018;187:45-60. DOI: 10.1016/j.pharmathera.2018.02.007.
]Search in Google Scholar
[
31. Bandaru P, Kondo Y, Kuriyan J. The interdependent activation of sonofsevenless and Ras. Cold Spring Harb Perspect Med. 2019;9(2):a031534. DOI: 10.1101/cshperspect.a031534.10.1101/cshperspect.a031534636087029610148
]Search in Google Scholar
[
32. Buffet C, Hecale-Perlemoine K, Bricaire L, Dumont F, Baudry C, Tissier F, et al. DUSP5 and DUSP6, two ERK specific phosphatases, are markers of a higher MAPK signaling activation in BRAF mutated thyroid cancers. PLoS ONE. 2017;12(9):e0184861. DOI: 10.1371/journal.pone.0184861.eCollection 2017.
]Search in Google Scholar
[
33. Cheng Y. Tian H. Current development status of MEK inhibitors. Molecules. 2017;22(10):1551. DOI: 10.3390/molecules22101551.10.3390/molecules22101551615181328954413
]Search in Google Scholar
[
34. Eblen ST. Extracellular regulated kinases: Signaling from Ras to ERK substrates to control biological outcomes. Adv Cancer Res. 2018;138:99-142. DOI: 10.1016/bs.acr.2018.02.004.10.1016/bs.acr.2018.02.004600798229551131
]Search in Google Scholar
[
35. Frodyma D, Neilsen B, Costanzo-Garvey D, Fisher K, Lewis R. Coordinating ERK signaling via the molecular scaffold Kinase Suppressor of Ras. F1000Res. 2017;6:1621. DOI: 10.12688/f1000research.11895. eCollection 2017.
]Search in Google Scholar
[
36. García-Gómez R, Bustelo XR, Crespo P. Protein-protein interactions: Emerging oncotargets in the RAS-ERK pathway. Trends Cancer. 2018;4(9):61633. DOI: 10.1016/j,trecan.2018.07.002.
]Search in Google Scholar
[
37. Geenen JJJ, Schellens JHM. Molecular pathways: targeting the protein kinase Wee1 in cancer. Clin Cancer Res. 2017;23(16):4540–4. DOI: 10.1158/1078-0432.CCR-17-0520.10.1158/1078-0432.CCR-17-052028442503
]Search in Google Scholar
[
38. Lavoie H, Therrien M. Regulation of RAF protein kinases in ERK signalling. Nat Rev Mol Cell Biol. 2015;16(5):281-98. DOI: 10.1038/nrm3979.10.1038/nrm397925907612
]Search in Google Scholar
[
39. Lawrence MC, Jivan A, Shao C, Duan L, Goad D, Zaganjor E, et al. The roles of MAPKs in disease. Cell Res. 2008;18(4):43642. DOI: 10.1038/cr.2008.37.10.1038/cr.2008.37
]Search in Google Scholar
[
40. Dohlman HG, Campbell SL. Regulation of large and small G proteins by ubiquitination. J Biol Chem. 2019;294(49):1861323. DOI: 10.1074/jbc.REV119.011068.10.1074/jbc.REV119.011068
]Search in Google Scholar
[
41. Dummer R, Schadendorf D, Ascierto PA, Arance A, Dutriaux C, Di Giacomo AM, et al. Binimetinib versus dacarbazine in patients with advanced NRAS-mutant melanoma (NEMO): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol. 2017;18(4):435-45. DOI: 10.1016/S1470-2045(17)30180-8.10.1016/S1470-2045(17)30180-8
]Search in Google Scholar
[
42. Herrero A, Pinto A, Colon-Bolea P, Casar B, Jones M, Agudo-Ibanez L, et al. Small molecule inhibition of ERK dimerization prevents tumorigenesis by RAS-ERK pathway oncogenes. Cancer Cell. 2015;28(2):170-82. DOI: 10.1016/j.ccell.2015.07.001.10.1016/j.ccell.2015.07.00126267534
]Search in Google Scholar
[
43. Simanshu DK, Nissley DV, McCormick F. RAS proteins and their regulators in human disease. Cell. 2017;170(1):1733. DOI: 10.1016/j.cell.2017.06.009.10.1016/j.cell.2017.06.009555561028666118
]Search in Google Scholar
[
44. Guo YJ, Pan WW, Liu SB, Shen ZF, Xu Y, Hu LL. ERK/MAPK signalling pathway and tumorigenesis. Exp Ther Med. 2020;19(3):1997-2007. DOI: 10.3892/etm.2020.8454.10.3892/etm.2020.8454702716332104259
]Search in Google Scholar
[
45. Khotskaya YB, Holla VR, Farago AF, Mills Shaw KR, Meric-Bernstam F, Hong DS. Targeting TRK family proteins in cancer. Pharmacol Ther. 2017;173:5866. DOI: 10.1016/j.pharmthera.2017.02.006.10.1016/j.pharmthera.2017.02.00628174090
]Search in Google Scholar
[
46. Sanchez JN, Wang T, Cohen MS. BRAF and MEK inhibitors: Use and resistance in BRAFmutated cancers. Drugs. 2018;78(5):54966. DOI: 10.1007/s40265-018-0884-8.10.1007/s40265-018-0884-8608061629488071
]Search in Google Scholar
[
47. Plotnikov A, Zehorai E, Procaccia S, Seger R. The MAPK cascades: Signaling components, nuclear roles and mechanisms of nuclear translocation. Biochim Biophys Acta Mol Cell Res. 2011;1813(9):161933. DOI: 10.1016/j.bbamcr.2010.12.012.10.1016/j.bbamcr.2010.12.01221167873
]Search in Google Scholar
[
48. Roskoski R Jr. ERK1/2 MAP kinases: Structure, function, and regulation. Pharmacol Res. 2012;66(2):10543. DOI: 10.1016/j.phrs.2012.04.005.10.1016/j.phrs.2012.04.00522569528
]Search in Google Scholar
[
49. Roskoski R Jr. Targeting ERK1/2 proteinserine/threonine kinases in human cancers. Pharmacol Res. 2019;142:15168. DOI: 10.1016/j.phrs.2019.01.039.10.1016/j.phrs.2019.01.03930794926
]Search in Google Scholar
[
50. Wainstein E, Seger R. The dynamic subcellular localization of ERK: mechanisms of translocation and role in various organelles. Curr Opin Cell Biol. 2016;39:1520. DOI: 10.1016/j.ceb.2016.01.007.10.1016/j.ceb.2016.01.00726827288
]Search in Google Scholar
[
51. Cassier E, Gallay N, Bourquard T, Claeysen S, Bockaert J, Crepieux P, et al. Phosphorylation of β-arrestin2 at Thr383 by MEK underlies β-arrestin-dependent activation of Erk1/2 by GPCRs. Elife. 2017;6:e23777. DOI: 10.7554/eLife.23777.10.7554/eLife.23777532562128169830
]Search in Google Scholar
[
52. Muñoz-Maldonado C, Zimmer Y, Medová M. A comparative analysis of individual RAS mutations in cancer biology. Front Oncol. 2019;9:1088. DOI: 10.3389/fonc.2019.01088. eCollection 2019.10.3389/fonc.2019.01088681320031681616
]Search in Google Scholar
[
53. Ma Y, Xu Y, Li L. SPARCL1 suppresses the proliferation and migration of human ovarian cancer cells via the MEK/ERK signaling. Exp Ther Med. 2018;16(4):3195-201. DOI: 10.3892/etm.2018.6575.10.3892/etm.2018.6575614384030233672
]Search in Google Scholar
[
54. Mahapatra DK, Asati V, Bharti SK. MEK inhibitors in oncology: a patent review (2015–Present). Expert Opin Ther Pat. 2017;27(8):887-906. DOI: 10.1080/13543776.2017.1339688.10.1080/13543776.2017.133968828594589
]Search in Google Scholar
[
55. Rukhlenko OS, Khorsand F, Krstic A, Rozanc J, Alexopoulos LG, Rauch N, et al. Dissecting RAF inhibitor resistance by structurebased modeling reveals ways to overcome oncogenic RAS signaling. Cell Syst. 2018;7(2):161179.e14. DOI: 10.1016/j.cels.2018.06.002.10.1016/j.cels.2018.06.002614954530007540
]Search in Google Scholar
[
56. Holderfield M, Deuker MM, McCormick F, McMahon M. Targeting RAF kinases for cancer therapy: BRAFmutated melanoma and beyond. Nat Rev Cancer. 2014;14(7):45567. DOI: 10.1038/nrc3760.10.1038/nrc3760425023024957944
]Search in Google Scholar
[
57. Vandamme D, Herrero A, AlMulla F, Kolch W. Regulation of the MAPK pathway by raf kinase inhibitory protein. Crit Rev Oncog. 2014;19(6):40515. DOI: 10.1615/critrevoncog.2014011922.10.1615/CritRevOncog.2014011922
]Search in Google Scholar
[
58. Colombino M, Capone M, Lissia A, Cossu A, Rubino C, De Giorgi V, et al. BRAF/NRAS mutation frequencies among primary tumors and metastases in patients with melanoma. J Clin Oncol. 2012;30(20):25229. DOI: 10.1200/JCO.2011.41.2452.10.1200/JCO.2011.41.245222614978
]Search in Google Scholar
[
59. Dankner M, Rose AAN, Rajkumar S, Siegel PM, Watson IR. Classifying BRAF alterations in cancer: new rational therapeutic strategies for actionable mutations. Oncogene. 2018;37(24):3183-199. DOI: 10.1038/s41388-018-0171-x.10.1038/s41388-018-0171-x29540830
]Search in Google Scholar
[
60. Sun W, Kesavan K, Schaefer BC, Garrington TP, Ware M, Johnson NL, et al. MEKK2 associates with the adapter protein Lad/RIBP and regulates the MEK5BMK1/ERK5 pathway. J Biol Chem. 2001;276(7):5093100. DOI: 10.1074/jbc.M003719200.10.1074/jbc.M00371920011073940
]Search in Google Scholar
[
61. Terrell EM, Morrison DK. Rasmediated activation of the Raf family kinases. Cold Spring Harb Perspect Med. 2019;9(1):a033746. DOI: 10.1101/cshperspect.a033746.10.1101/cshperspect.a033746631114929358316
]Search in Google Scholar
[
62. Jones JC, Renfro LA, Al-Shamsi HO, Schrock AB, Rankin A, Zhang BY, et al. NonV600 BRAF mutations define a clinically distinct molecular subtype of metastatic colorectal cancer. J Clin Oncol. 2017;35(23):262430. DOI: 10.1200/JCO.2016.71.4394.10.1200/JCO.2016.71.4394554945428486044
]Search in Google Scholar
[
63. Seternes OM, Kidger AM, Keyse SM. Dual-specificity MAP kinase phosphatases in health and disease. Biochim Biophys Acta Mol Cell Res. 2019;1866(1):12443. DOI: 10.1016/j.bbamcr.2018.09.002.10.1016/j.bbamcr.2018.09.002622738030401534
]Search in Google Scholar
[
64. Wang C, Chen Z, Nie L, Tang M, Feng X, Su D, et al. Extracellular signal-regulated kinases associate with and phosphorylate DHPS to promote cell proliferation. Oncogenesis. 2020;9(9):85. DOI: 10.1038/s41389-020-00271-1.10.1038/s41389-020-00271-1752227832989218
]Search in Google Scholar
[
65. Zhou B, Der CJ, Cox AD. The role of wild type RAS isoforms in cancer. Semin Cell Dev Biol. 2016;58:609. DOI: 10.1016/j.semcdb.2016.07.012.10.1016/j.semcdb.2016.07.012502830327422332
]Search in Google Scholar
[
66. Lu P, Chen J, Yan L, Yang L, Zhang L, Dai J, et al. RasGRF2 promotes migration and invasion of colorectal cancer cells by modulating expression of MMP9 through Src/Akt/NF-kappaB pathway. Cancer Biol Ther. 2018;20(4):435-43. DOI: 10.1080/15384047.2018.1529117.10.1080/15384047.2018.1529117642250330359168
]Search in Google Scholar
[
67. Krishnamoorthy GP, Davidson NR, Leach SD, Zhao Z, Lowe SW, Lee G, et al. EIF1AX and RAS mutations cooperate to drive thyroid tumorigenesis through ATF4 and c-MYC. Cancer Discovery. 2019;9(2):264-81. DOI: 10.1158/2159-8290.CD-18-0606.10.1158/2159-8290.CD-18-0606637345130305285
]Search in Google Scholar
[
68. Lavoie H, Sahmi M, Maisonneuve P, Marullo SA, Thevakumaran N, Jin T, et al. MEK drives BRAF activation through allosteric control of KSR proteins. Nature. 2018;554:549-53.10.1038/nature25478643312029433126
]Search in Google Scholar
[
69. Song M, Finley SD. Mechanistic insight into activation of MAPK signaling by pro-angiogenic factors. BMC Syst Biol. 2018;12:145. DOI: 10.1186/s12918-018-0668-5.10.1186/s12918-018-0668-5
]Search in Google Scholar
[
70. Vladimirova LY. The use of MEK inhibitors in oncology: results and prospects. Success of Modern Natural Science. 2015;3:18-30.
]Search in Google Scholar
[
71. Rubinfeld H, Seger R. The ERK cascade: a prototype of MAPK signaling. Mol Biotechnol. 2005;31(2):15174. DOI: 10.1385/MB:31:2:151.10.1385/MB:31:2:151
]Search in Google Scholar
[
72. Tang Q, Wu J, Zheng F, Hann SS, Chen YQ. Emodin increases expression of insulinlike growth factor binding protein 1 through activation of MEK/ERK/AMPKα and interaction of PPARγ and Sp1 in lung cancer. Cell Physiol Biochem. 2017;41(1):33957. DOI: 10.1159/000456281.10.1159/00045628128214826
]Search in Google Scholar
[
73. Wood LD, Parsons DW, Jones S, Lin J, Sjoblom T, Leary RJ, et al. The genomic landscapes of human breast and colorectal cancers. Science. 2007;318(5853):1108-13. DOI: 10.1126/science.1145720.10.1126/science.114572017932254
]Search in Google Scholar
[
74. Yang S, Liu G. Targeting the Ras/Raf/MEK/ERK pathway in hepatocellular carcinoma. Oncol Lett. 2017;13(3):10417. DOI: 10.3892/ol.2017.5557.10.3892/ol.2017.5557540324428454211
]Search in Google Scholar
[
75. Mandal R, Becker S, Strebhardt K. Stamping out RAF and MEK1/2 to inhibit the ERK1/2 pathway: an emerging threat to anticancer therapy. Oncogene. 2016;35(20):2547-61. DOI: 10.1038/onc.2015.329.10.1038/onc.2015.32926364606
]Search in Google Scholar
[
76. Gialeli C, Theocharis AD, Karamanos NK. Roles of matrix metalloproteinases in cancer progression and their pharmacological targeting. FEBS J. 2011;278(1):16-27. DOI: 10.1111/j.1742-4658.2010.07919.x10.1111/j.1742-4658.2010.07919.x21087457
]Search in Google Scholar
[
77. Braicu C, Buse M, Busuioc C, Drula R, Gulei D, Raduly L, et al. A comprehensive review on MAPK: A promising therapeutic target in cancer. Cancers (Basel). 2019;11(10):1618. DOI: 10.3390/cancers11101618.10.3390/cancers11101618682704731652660
]Search in Google Scholar
[
78. Caunt CJ, Sale MJ, Smith PD, Cook SJ. MEK1 and MEK2 inhibitors and cancer therapy: the long and winding road. Nat Rev Cancer. 2015;15(10):577-92. DOI: 10.1038/nrc4000.10.1038/nrc400026399658
]Search in Google Scholar
[
79. Krishna Priya S, Nagare RP, Sneha VS, Sidhanth C, Bindhya S, Manasa P, Ganesan TS. Tumour angiogenesis-Origin of blood vessels. Int J Cancer. 2016;139(4):729-35. DOI: 10.1002/ijc.30067.10.1002/ijc.3006726934471
]Search in Google Scholar
[
80. Bian CX, Shi Z, Meng Q, Jiang Y, Liu LZ, Jiang BH. P70S6K 1 regulation of angiogenesis through VEGF and HIF-1alpha expression. Biochem Biophys Res Commun. 2010;398(3):395-9. DOI: 10.1016/j.bbrc.2010.06.080.10.1016/j.bbrc.2010.06.080292806120599538
]Search in Google Scholar